Quick Answer
Xilio Therapeutics, Inc. reported Operating Income of -$41.98 million for fiscal year 2025.
Xilio Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$41.98M | +30.7% |
| 2024 | -$60.58M | +23.4% |
| 2023 | -$79.13M | +11.2% |
| 2022 | -$89.15M | -18.8% |
| 2021 | -$75.04M | -37.5% |
| 2020 | -$54.56M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.93M | +86.9% | +86.6% |
| June 30, 2025 | -$14.37M | +2.3% | -3.7% |
| March 31, 2025 | -$13.85M | +20.8% | +6.2% |
| September 30, 2024 | -$14.76M | +15.0% | -0.4% |
| June 30, 2024 | -$14.70M | +26.9% | +15.9% |
| March 31, 2024 | -$17.49M | +25.7% | -0.7% |
| September 30, 2023 | -$17.36M | +14.1% | +13.7% |
| June 30, 2023 | -$20.12M | +18.1% | +14.5% |
- Xilio Therapeutics, Inc. showed an increase of +30.7% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Xilio Therapeutics, Inc.’s operating income has grown by 23.1% (from -$54.56 million to -$41.98 million).
- The most recent figure is from Xilio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: